FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER

被引：0
|
作者：
Andretta, V [1 ]
Bennicelli, E. [1 ]
Pessino, A. [1 ]
Caprioni, F. [1 ]
Decian, F. [1 ]
Di Benedetto, M. [1 ]
Sobrero, A. [1 ]
机构：
[1] Azienda Osped Univ San Martino Genova, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant treatment with Bevacizumab and folfox-6 in patients with liver metastasis from colorectal cancer: Preliminary results of a phase II study
    Bertolini, F.
    Malavasi, N.
    Dealis, C.
    Zroni, S.
    Depenni, R.
    Fontana, A.
    Sternieri, R.
    Ponti, G.
    Luppi, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [22] Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
    Jafari, Abdosaleh
    Tabatabaei Far, Sedighe Sadat
    Dehghani, Mehdi
    Ravangard, Ramin
    CANCER CONTROL, 2023, 30
  • [23] "CHARTA": FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer; a multivariate analysis of prognostic and predictive factors
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Schmoll, H. -J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 162 - 162
  • [24] Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
    Infante, Jeffrey R.
    Reid, Tony R.
    Cohn, Allen L.
    Edenfield, William J.
    Cescon, Terrence P.
    Hamm, John T.
    Malik, Imtiaz A.
    Rado, Thomas A.
    McGee, Philip J.
    Richards, Donald A.
    Tarazi, Jamal
    Rosbrook, Brad
    Kim, Sinil
    Cartwright, Thomas H.
    CANCER, 2013, 119 (14) : 2555 - 2563
  • [25] FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
    Bokemeyer, C.
    Koehne, C. -H.
    Ciardiello, F.
    Lenz, H. -J.
    Heinemann, V.
    Klinkhardt, U.
    Beier, F.
    Duecker, K.
    van Krieken, J. H.
    Tejpar, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) : 1243 - 1252
  • [26] RESULTS FROM THE CELIM STUDY: CETUXIMAB PLUS FOLFOX6 OR CETUXIMAB PLUS FOLFIRI AS NEOADJUVANT TREATMENT FOR NONRESECTABLE COLORECTAL CANCER LIVER METASTASES
    Koehne, C.
    Gruenberger, T.
    Bechstein, W.
    Hartmann, J.
    Lang, H.
    Lordick, F.
    Herrmann, T.
    Stoehlmacher, J.
    Frilling, A.
    Raab, H.
    Liersch, T.
    Ockert, D.
    Konopke, R.
    Weitz, J.
    Folprecht, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 23
  • [27] Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
    Otsu, Satoshi
    Hirashima, Yoshinori
    Nishikawa, Kazuo
    Sakashita, Hiroyuki
    Morinaga, Ryotaro
    Watanabe, Koichiro
    Shirao, Kuniaki
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 19 - 23
  • [28] A phase I trial of imatinib (IM) plus mFOLFOX-bevacizumab in patients with advanced colorectal cancer
    Michael, M.
    Tebbutt, N. C.
    Gibbs, P.
    Lipton, L. R.
    Jefford, M.
    Milner, A.
    Gouillou, M.
    Hatzimihalis, A.
    McArthur, G. A.
    Zalcberg, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
    Wang, Feng
    Xiao, Jian
    Zhang, Yan-Qiao
    Yuan, Xianglin
    Fang, Weijia
    Wang, Wei
    Hu, Xiaohua
    Zhuang, Zhixiang
    Zhou, Fuxiang
    Ying, Jieer
    Yuan, Ying
    Guo, Zeng-qing
    Wu, XiangYuan
    Zou, Qing-Feng
    He, Ming-ming
    Guo, Ying
    Chen, Shuang-Zhen
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
    Bond, M. J. G.
    van Smeden, M.
    Degeling, K.
    Cremolini, C.
    Schmoll, H. J. E-V.
    Rossini, D.
    Ibach, S.
    Koopman, M.
    Punt, C. J. A.
    May, A. M.
    Kwakman, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
12345